Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) on July 24, setting a price target of $33.00.

The analyst told investors that NovoCure Limited (NASDAQ:NVCR) reported solid results for fiscal Q2 2025, exceeding revenue expectations with a total of $158.8 million. This growth was attributed to a rise in active patient numbers across major markets, suggesting solid demand for the products.

Chang added that despite the initial mixed metrics for the launch of Optune Lua in non-small cell lung cancer (NSCLC), prescriptions and active patients underwent a notable growth, suggesting potential for future growth.

NovoCure Limited (NASDAQ:NVCR) develops, manufactures, and commercializes Optune to treat a number of solid tumors. The company’s platform is called Tumor Treating Field, and it employs electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

While we acknowledge the potential of NVCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.